CRIT is expressed on podocytes in normal human kidney and upregulated in membranous nephropathy

Kidney International

Volumn 69, Issue 11, 2006, Pages 1961-1968

  Moll, S ^a   Lange, S ^b   Mihatsch, M J ^c   Dragic, Z ^b   Schifferli, J A ^b   Inal, J M ^b,d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Complement C2 receptor inhibitor trispanning (CRIT); Complement system; Glomerulopathy; Immunohistochemistry; Membranous nephropathy; Podocyte

Indexed keywords

CELL SURFACE RECEPTOR; COMPLEMENT COMPONENT C2 RECEPTOR INHIBITOR TRISPANNING PROTEIN; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL PROTECTION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY ARTERY; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR BINDING; RNA TRANSCRIPTION;

CARRIER PROTEINS; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; KIDNEY; PODOCYTES; UP-REGULATION;

EID: 33745238895     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000379     Document Type: Article

References (43)

1. Johnson RJ. Involvement of complement components in renal disease. Curr Opin Nephrol Hypertens 1997; 6: 120-127.
2. Hsu SI, Couser WG. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol 2003; 14: S186-S191.
3. Matsuo S, Morita Y, Mizuno M et al. The role of complement in the progression of renal fibrosis: a clinical study. Nephrol Dial Transplant 2000; 15(Suppl 6): 53-54.
4. Raij L, Dalmasso AP, Staley NA et al. Renal injury in DOCA-salt hypertensive C5-sufficient and C5-deficient mice. Kidney Int 1989; 36: 582-592.
5. Pickering MC, Cook HT, Warren J et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31: 424-428.
6. Hogasen K, Jansen JH, Mollnes TE et al. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995; 95: 1054-1061.
7. Quigg RJ, Holers VM, Morgan BP et al. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol 1995; 154: 3437-3443.
8. Couser WG, Johnson RJ, Young BA et al. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995; 5: 1888-1894.
9. Nishikage H, Baranyi L, Okada H et al. The role of a complement regulatory protein in rat mesangial glomerulonephritis. J Am Soc Nephrol 1995; 6: 234-241.
10. Hatanaka Y, Yuzawa Y, Nishikawa K et al. Role of a rat membrane inhibitor of complement in anti-basement membrane antibody-induced renal injury. Kidney Int 1995; 48: 1728-1737.
11. Inal JM, Pascual M, Lesavre P et al. Complement inhibition in renal diseases. Nephrol Dial Transplant 2003; 18: 237-240.
12. Cosio FG, Sedmak DD, Mahan JD et al. Localization of decay accelerating factor in normal and diseased kidneys. Kidney Int 1989; 36: 100-107.
13. Abe K, Miyazaki M, Koji T et al. Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney. Kidney Int 1998; 54: 120-130.
14. Ichida S, Yuzawa Y, Okada H et al. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 1994; 46: 89-96.
15. Endoh M, Yamashina M, Ohi H et al. Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin Exp Immunol 1993; 94: 182-188.
16. Nakanishi I, Moutabarrik A, Hara T et al. Identification and characterization of membrane cofactor protein (CD46) in the human kidneys. Eur J Immunol 1994; 24: 1529-1535.
17. Kazatchkine MD, Fearon DT, Appay MD et al. Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy-five cases of renal diseases: loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of systemic lupus erythematosus. J Clin Invest 1982; 69: 900-912.
18. Fischer E, Appay MD, Cook J et al. Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor. J Immunol 1986; 136: 1373-1377.
19. Tamai H, Matsuo S, Fukatsu A et al. Localization of 20-kD homologous restriction factor (HRF20) in diseased human glomeruli. An immunofluorescence study. Clin Exp Immunol 1991; 84: 256-262.
20. Bridgewater DJ, Mok A, Matsell DG. Expression of complement regulatory proteins in the developing human kidney. Pediatr Nephrol 2000; 15: 36-42.
21. Meri S, Waldmann H, Lachmann PJ. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 1991; 65: 532-537.
22. Moll S, Miot S, Sadallah S et al. No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int 2001; 59: 160-168.
23. Arora M, Arora R, Tiwari SC et al. Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis. Lupus 2000; 9: 127-131.
24. Arora V, Verma J, Dutta R et al. Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus. Mol Immunol 2004; 41: 449-456.
25. Nangaku M. Complement regulatory proteins in glomerular diseases. Kidney Int 1998; 54: 1419-1428.
26. Lehto T, Honkanen E, Teppo AM et al. Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int 1995; 47: 1403-1411.
27. Inal JM. Schistosoma TOR (trispanning orphan receptor), a novel, antigenic surface receptor of the blood-dwelling, Schistosoma parasite. Biochim Biophys Acta 1999; 1445: 283-298.
28. Inal JM, Hui KM, Miot S et al. Complement C2 receptor inhibitor trispanning: a novel human complement inhibitory receptor. J Immunol 2005; 174: 356-366.
29. Inal JM, Schifferli JA. Complement C2 receptor inhibitor trispanning and the beta-chain of C4 share a binding site for complement C2. J Immunol 2002; 168: 5213-5221.
30. Inal JM, Schneider B, Armanini M et al. A peptide derived from the parasite receptor, complement C2 receptor inhibitor trispanning, suppresses immune complex-mediated inflammation in mice. J Immunol 2003; 170: 4310-4317.
31. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
32. Lin F, Salant DJ, Meyerson H et al. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. J Immunol 2004; 172: 2636-2642.
33. Bao L, Spiller OB, St John PL et al. Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney Int 2002; 62: 2010-2021.
34. Debiec H, Guigonis V, Mougenot B et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002; 346: 2053-2060.
35. Cunningham PN, Hack BK, Ren G et al. Glomerular complement regulation is overwhelmed in passive Heymann nephritis. Kidney Int 2001; 60: 900-909.
36. Mathieson PW. What has the immune system got against the glomerular podocyte? Clin Exp Immunol 2003; 134: 1-5.
37. Adler S, Baker PJ, Pritzl P et al. Detection of terminal complement components in experimental immune glomerular injury. Kidney Int 1984; 26: 830-837.
38. Kerjaschki D, Neale TJ. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 1996; 7: 2518-2526.
39. Mudge SJ, Paizis K, Auwardt RB et al. Activation of nuclear factor-kappa B by podocytes in the autologous phase of passive Heymann nephritis. Kidney Int 2001; 59: 923-931.
40. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001; 108: 1583-1587.
41. Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech 2002; 57: 189-195.
42. Hara M, Yanagihara T, Kihara I et al. Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury. J Am Soc Nephrol 2005; 16: 408-416.
43. Lange S, Dodds AW, Gudmundsdottir S et al. The ontogenic transcription of complement component C3 and apolipoprotein A-I tRNA in Atlantic cod (Gadus morhua L.) - a role in development and homeostasis? Dev Comp Immunol 2005; 29: 1065-1077.